Login to Your Account



Aytu bad, Endo: Acerus replacement in $45.5M U.S. testosterone tie-up

By Randy Osborne
Staff Writer

Monday, April 25, 2016

Aytu Bioscience Inc. CEO Josh Disbrow said that confusion over what endpoints might be acceptable to the FDA in trials with therapies for low testosterone "is a bit of an anomaly, and frankly we view it to some degree as a barrier to entry that's relatively unique."

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription